{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:03:00Z","timestamp":1790352180919,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004699","name":"Chung Shan Medical University Hospital","doi-asserted-by":"publisher","award":["CSH-2023-C-001"],"award-info":[{"award-number":["CSH-2023-C-001"]}],"id":[{"id":"10.13039\/501100004699","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolism"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.diabet.2026.101785","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:15:50Z","timestamp":1785856550000},"page":"101785","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative effectiveness of sodium\u2013glucose cotransporter-2 versus dipeptidyl peptidase-4 inhibitors on all-cause mortality in type 2 diabetes: a multinational propensity score\u2013matched cohort study"],"prefix":"10.1016","volume":"52","author":[{"given":"Ching-Yu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Li","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Wen","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7786-5497","authenticated-orcid":false,"given":"Gwo-Ping","family":"Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2026.101785_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabet.2026.101785_bib0002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057873","article-title":"The relationship of sugar to population-level diabetes prevalence: an econometric analysis of repeated cross-sectional data","volume":"8","author":"Basu","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.diabet.2026.101785_bib0003","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics\u20142019 update: a report from the American heart association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2026.101785_bib0004","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.2337\/dci15-0012","article-title":"Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American heart association and the American diabetes association","volume":"38","author":"Fox","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2026.101785_bib0005","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1056\/NEJMoa051530","article-title":"Outcome of heart failure with preserved ejection fraction in a population-based study","volume":"355","author":"Bhatia","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2026.101785_bib0006","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10741-020-10005-5","article-title":"Dipeptidyl peptidase-4 inhibitors as new tools for cardioprotection","volume":"26","author":"Rankovic","year":"2021","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.diabet.2026.101785_bib0007","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/14740338.2017.1239707","article-title":"Cardiovascular safety of therapies for type 2 diabetes","volume":"16","author":"Gupta","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.diabet.2026.101785_bib0008","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2026.101785_bib0009","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2337\/dc14-1850","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 trial","volume":"38","author":"Udell","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2026.101785_bib0010","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2010.11.002","article-title":"Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications","volume":"124","author":"Nauck","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.diabet.2026.101785_bib0011","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2026.101785_bib0012","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2026.101785_bib0013","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2026.101785_bib0014","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2026.101785_bib0015","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. a consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2026.101785_bib0016","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.2337\/dc20-1890","article-title":"Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial using health care databases","volume":"43","author":"Xie","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2026.101785_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1516126","article-title":"A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX","volume":"16","author":"Ludwig","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.diabet.2026.101785_bib0018","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/jdi.14361","article-title":"Enhanced renoprotective effects of combined glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: real-world evidence","volume":"16","author":"Jhu","year":"2025","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.diabet.2026.101785_bib0019","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1111\/dom.15708","article-title":"Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all-cause mortality in adults, compared with bisphosphonates: an analysis of real-world, cohort data, with a systematic review and meta-analysis","volume":"26","author":"Henney","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2026.101785_bib0020","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1001\/jamapsychiatry.2025.0200","article-title":"Esketamine combined with SSRI or SNRI for treatment-resistant depression","volume":"82","author":"Del Casale","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.diabet.2026.101785_bib0021","first-page":"242","article-title":"Are there any renoprotective effects of SGLT2 inhibitors in heart transplant recipients with diabetes?","volume":"41","author":"Lu","year":"2025","journal-title":"Acta Cardiol Sin"},{"key":"10.1016\/j.diabet.2026.101785_bib0022","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","article-title":"Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2026.101785_bib0023","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1016\/j.jacc.2018.03.009","article-title":"Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study","volume":"71","author":"Kosiborod","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2026.101785_bib0024","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2026.101785_bib0025","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/01.JAA.0000533660.86287.04","article-title":"The role of SGLT2 inhibitors in managing type 2 diabetes","volume":"31","author":"Tat","year":"2018","journal-title":"JAAPA"},{"key":"10.1016\/j.diabet.2026.101785_bib0026","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2026.101785_bib0027","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jamainternmed.2022.6664","article-title":"comparing effectiveness and safety of sglt2 inhibitors vs dpp-4 inhibitors in patients with type 2 diabetes and varying baseline HbA1c levels","volume":"183","author":"D'Andrea","year":"2023","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.diabet.2026.101785_bib0028","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diabet.2026.101785_bib0029","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/pds.3586","article-title":"The long-term efficacy and safety of DPP-IV inhibitors monotherapy and in combination with metformin in 18,980 patients with type-2 diabetes mellitus\u2013a meta-analysis","volume":"23","author":"Liu","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.diabet.2026.101785_bib0030","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1164\/rccm.200802-282OC","article-title":"Mortality reduction with influenza vaccine in patients with pneumonia outside \"flu\" season: pleiotropic benefits or residual confounding?","volume":"178","author":"Eurich","year":"2008","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363626000649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363626000649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:09:20Z","timestamp":1790348960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363626000649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1262363626000649"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2026.101785","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness of sodium\u2013glucose cotransporter-2 versus dipeptidyl peptidase-4 inhibitors on all-cause mortality in type 2 diabetes: a multinational propensity score\u2013matched cohort study","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2026.101785","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101785"}}